Corporate Educational Satellite Symposia

Subpage Hero

Corporate Educational Satellite Symposia

Corporate Educational Satellite Symposia are independently developed and supported by ACMG’s industry partners and offer additional valuable educational opportunities for attendees. These sessions provide updates on cutting edge products, services and treatments, presentations regarding new and innovative
developments, and insights from Industry. Corporate Satellite Symposia are not part of the official ACMG program and are open to all attendees. 

Pre-registration for each Symposium is required, links are provided below in each session description

Sanofi

Pulmonology and Medical Genetics: A Multidisciplinary Approach to Diagnosis and Management In Rare Disease

Tuesday, March 14: 2:00 PM - 3:30 PM
Hyatt Regency Salt Lake City

A case-based discussion illustrating a best-practice approach to a "mystery diagnosis" case who presented to pulmonology with respiratory deficiency to rule out COVID19. Subsequent work-up revealed symptoms of metabolic disease. Patient was subsequently diagnosed with ASMD.

Learning Objectives:

  • Understand overlap of ASMD and Gaucher signs/symptoms including respiratory aspects
  • Understand overlap of ASMD and Gaucher signs/symptoms including respiratory aspects
  • Understand recommendations for monitoring ASMD and Gaucher and appreciate the benefit of multi-disciplinary coordination

Speakers:
Manisha Balwani, MD, MS, FACMG, Icahn School of Medicine at Mount Sinai  
Nicole Ng, MD, PharmD, Icahn School of Medicine at Mount Sinai                   

Not Accredited

For more information and to register:  TBA

Takeda Pharmaceuticals, Inc

Keeping Ahead of the Curve: Emerging Biomarker Strategies for Lysosomal Storage Diseases
(This activity is supported by an independent educational grant from Takeda Pharmaceuticals, Inc.)

Tuesday, March 14: 2:00 PM - 3:30 PM
Hyatt Regency Salt Lake City

This symposium will focus on the historical, current, and future use of biomarkers to diagnose, treat, and monitor patients with Lysosomal Storage Diseases, or LSDs. Each of 3 presentations will consist of a didactic session followed by a clinical case involving an LSD with unexpected twists or curveballs.

Learning Objectives:

  • Describe the history and evolution of biomarkers in the diagnosis and monitoring of Lysosomal Storage Diseases (LSDs)
  • Appraise the value of new and emerging disease-specific biomarkers to detect early pathologies, track disease progression, and monitor response to therapy
  • Evaluate how omics-driven biomarker development strategies can support clinical decision making and personalization efforts in GD (Gaucher disease), MPS II (Mucopolysaccharidosis type II), and MLD (Metachromatic leukodystrophy)

Speakers:
Priya Kishnani, MD, MBBS, FACMG, Duke University School of Medicine
Barbara K. Burton, MD, FACMG, Ann & Robert H. Lurie Children’s Hospital of Chicago
Marc Patterson, MD, Mayo Clinic

Accredited: Yes 1.5 hours

For more information and to register

Illumina

Implementing Whole Genome Sequencing for Newborn Screening:  Perspectives from 4 Pilot Programs
(This activity is supported by an independent educational grant from Illumina) 

Tuesday, March 14: 4:00 PM - 5:30 PM
Hyatt Regency Salt Lake City

The use of WHS has the potential to radically alter the genetic HCPs relationship to genetic disease. Instead of assessing and reacting to a phenotype, these HCPs will be called upon to manage disorders before symptoms arise, having consequences for geneticists, GCs, and pediatric specialists that treat these diseases. Policymakers involved in current state screening programs will need to consider how to respond. This CME activity will provide essential knowledge of the many key issues that must be addressed when NBS by genome sequencing is to be implemented into routine practice.

Learning Objectives:

  • Describe how current NBS differs from screening that will employ genome sequencing
  • List three advantages of genome sequencing compared to current newborn screening
  • List challenges associated with the use of genome sequencing and how to potentially overcome them
  • Compare different approaches to NBS by genome sequencing implemented at 4 different pilot programs
  • Recognize how early diagnosis by WGS can enable a change in clinical management, including shortened time to diagnosis, effective treatment options, avoidance of unnecessary testing, referral to specialists, opportunities for experimental treatment and/or decisions regarding palliative care.

Speakers:
David P. Bick, MD, FACMG, Queen Mary University of London, Genomics England
Richard Scott, MD, Queen Mary University of London, Genomics England
Richard C. Green, MD, MPH, Harvard Medical School, Brigham And Women's Hospital
Wendy K. Chung, MD, PhD, FACMG, Columbia University
Stephen Kingsmore, MD, DSc, Rady Children's Institute for Genomic Medicine

Accredited:  Yes, 1.5 hours

For more information and to register

Chiesi Global Rare Diseases

Understanding the Diagnostic Odyssey of Alpha Mannosidosis 
(This activity is supported by an independent educational grant from Chiesi Global Rare Diseases)

Tuesday, March 14, 2023 – 4:00 pm – 5:30 pm
Hyatt Regency Salt Lake City

Alpha mannosidosis is a rare genetic disorder characterized by the inability to breakdown mannose in lysosomes. Alpha mannosidosis affects multiple organs and its symptoms can vary widely. The goal of this program is to help clinicians distinguish alpha mannosidosis from other lysosomal storage disorders that often present similarly.

Learning Objectives: 

  • Identify signs and symptoms of alpha mannosidosis
  • Present typical and atypical cases of pediatric- and adult-onset alpha mannosidosis
  • Discuss challenges that contribute to an unnecessarily long diagnostic journey

Speakers:
Barbara Burton, MD, FACMG, Ann & Robert H. Lurie Children's Hospital of Chicago
Karolina Stepien, MD, PhD, Mark Holland Metabolic Unit, Salford Royal NHS Foundation Trust
Florian Lagler, MD, PhD, Clinical Research Center Salzburg GmbH
Nicole Muschol, PhD, International Center for Lysosomal Disorders (ICLD), University Medical Center Hamburg-Eppendorf

For more information and to register:  TBA

Amicus Therapeutics

Fabry Patient Cases: When to Consider Fabry Treatment
(This activity is supported by an independent educational grant from Amicus Therapeutics)

Tuesday, March 14: 6:00 PM - 7:30 PM
Hyatt Regency Salt Lake City

A case-based presentation focused on when to consider a novel treatment option for Fabry disease. 

Learning Objectives:

  • Understand a novel treatment option for Fabry disease
  • Review patient cases to better inform initiating and switching the appropriate patients 
  • Describe the real-world factors of treating a patient along with appropriate monitoring

Speakers:
Rob Hopkin, MD, Cincinnati Children’s Hospital Medical Center

Not Accredited

For more information and to register:  TBA

Sponsors